Saudi Pharmaceutical Industries and Medical Appliances has signed a non-binding memorandum of understanding with CureVac to provide a COVID-19 vaccine in Saudi Arabia, reported Bloomberg.
Saudi Pharma said the availability of the vaccine is subject to approval from the kingdom’s Ministry of Health and Food and Drug Authority.
The agreement includes the possibility of extending the supply and distribution rights in the United Arab Emirates, Kuwait, Bahrain, and Oman.
CureVac’s COVID-19 vaccine candidate showed a good immune response in early trials and its chief executive officer said advanced clinical trials are on track to start by the end of the year.
The European Union has agreed to pay $11.84 per dose for an initial supply of 225 million doses of CureVac’s vaccine.
To read more NewsPoints articles, click here.